Back to search page

trfr20170807001

A French company is looking for a co-development agreement for its anti cancer small molecule

TECHNOLOGY PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

A French company is developing a novel molecule to be used as a first or second line in the treatment of chemoresistant cancers.

The company is looking for technical cooperation agreements with biotech and pharmaceutical partners with complementary expertise.


FULL DESCRIPTION

The French company develops new, first-in-class drugs that meet unfulfilled medical needs in the fields of oncology and inflammatory diseases and notably for indications of rare diseases.

The activity is based on acquiring licensing options for technologies at an early stage of development, following the detection and early co-maturation of innovative projects derived from Universities, and then develop the technology until reaching clinical phase I/IIA and license-out to a Pharmaceutical company.

The company is developing a first-in-class new chemical entity (NCE), small molecule, which is highly specific and cytotoxic for cancer cells (nanomolar level). It has a 3-step synergic sequential mechanism of action (3 in 1 moiety):

1 - Inhibition of the translation machinery in cancer cells;
2 - Cell cycle arrest and apoptosis activation;
3 - Activation of interferon-mediated responses, sustaining apoptosis.

The company intends to develop it as a novel treatment to be integrated in the arsenal of drugs for first or second line of treatment for chemoresistant tumors, to be used alone or in combination with other drugs or within an antibody-drug conjugate (ADC) strategy.


Partner expertise sought:

- Type of partner sought: The company is looking for:
- all-size biotech and pharmaceutical partners with a complementary expertise in oncology drug development, in order to support the preclinical development of the anti-cancer small molecule via a co-development agreement.
- Specific area of activity of the partner: We are open to co-development agreement with Biotech/Pharma partner.


Development Stage:

Concept stage


IPR:

Patents granted

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
FRANCE
Profile date
16/01/2018
Deadline
01/09/2018

PARTNERSHIP(S) SOUGHT

Technical cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Biosciences and Health \ Drug Discovery and Drug Development \ Diagnostics \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Cytology, Cancerology, Oncology / BIOLOGICAL SCIENCES / Medicine, Human Health / Medical Research / BIOLOGICAL SCIENCES / Biology / Biotechnology
COMMERCIAL KEYWORDS
Research and experimental development on biotechnology
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Clinical Medicine / Oncology / MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number trfr20170807001